PrecisionMed, LLC

PrecisionMed, LLC, based in the US, specializes in high-quality human biological samples for research, primarily focusing on Cerebral Spinal Fluid (CSF) and other biological materials essential for scientific advancements. Founded in 1994 in Carlsbad, US, PrecisionMed, LLC operates as a provider of human biological samples for research. The company was acquired by BioIVT, LLC, on July 18, 2023, from West-Atlantic Partners, LLC. It has successfully completed 2 deals to date.

PrecisionMed specializes in providing high-quality human biological samples for research, focusing on Cerebral Spinal Fluid (CSF), serum, plasma, and various biological materials. It maintains the world's largest private CSF biorepository, which includes longitudinal samples with matched clinical data. The biorepository is compliant with strict regulatory standards and includes diverse sample types such as CSF Cell Pellets, DNA/EDTA blood pellets, PAXGene RNA, serum, plasma, and urine. The primary customers include major pharmaceutical, biotechnology firms, and academic and government research institutions globally, with notable clients like Harvard Medical School, Biogen, and GlaxoSmithKline.

PrecisionMed's products are utilized in research sectors across North America, Europe, and Asia, particularly in neurology, oncology, and biomarker discovery. PrecisionMed operates on a transactional model primarily focused on business-to-business (B2B) relationships. Its revenue structure comprises direct sales of biological samples, where clients order specific types from its extensive inventory. The transaction process generally includes agreements outlining service terms, including sample delivery times and quality assurances.

While specific pricing details are not disclosed, flagship products like Diseased and TruNormal® CSF samples play a crucial role in various research studies. The operational model prioritizes immediate availability and high-quality standards, ensuring support for scientific research and innovation. Following the acquisition by BioIVT, LLC, in July 2023, PrecisionMed aims to enhance its engagement with the research community, leveraging combined resources to improve patient outcomes. The integration will facilitate the development of new products tailored to research needs, although specific launch dates are yet to be disclosed.

The companies plan to expand their market presence in North America, Europe, and Asia, targeting growth initiatives that align with ongoing research collaboration opportunities.